
    
      This is a single arm, open-label, single-center study. This study is indicated for relapsed
      BCMA+ multiple myeloma, the selections of dose levels and the number of subjects are based on
      clinical trials of similar foreign products. 50 patients will be enrolled for this trial.
      Primary objective is to explore the safety, main consideration is dose-related safety.
    
  